Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
INFI's Cash to Debt is ranked higher than
87% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. INFI: No Debt )
INFI' s 10-Year Cash to Debt Range
Min: 0.93   Max: No Debt
Current: No Debt

Equity to Asset 0.57
INFI's Equity to Asset is ranked higher than
67% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INFI: 0.57 )
INFI' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.94
Current: 0.57

0.12
0.94
F-Score: 5
Z-Score: 2.38
M-Score: 2.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -4.80
INFI's Operating margin (%) is ranked higher than
82% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -83.68 vs. INFI: -4.80 )
INFI' s 10-Year Operating margin (%) Range
Min: -6986.21   Max: 22.94
Current: -4.8

-6986.21
22.94
Net-margin (%) -10.55
INFI's Net-margin (%) is ranked higher than
81% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. INFI: -10.55 )
INFI' s 10-Year Net-margin (%) Range
Min: -6967.24   Max: 28.35
Current: -10.55

-6967.24
28.35
ROE (%) -9.00
INFI's ROE (%) is ranked higher than
82% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. INFI: -9.00 )
INFI' s 10-Year ROE (%) Range
Min: -123.36   Max: 27.59
Current: -9

-123.36
27.59
ROA (%) -6.39
INFI's ROA (%) is ranked higher than
83% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. INFI: -6.39 )
INFI' s 10-Year ROA (%) Range
Min: -51.92   Max: 16.29
Current: -6.39

-51.92
16.29
ROC (Joel Greenblatt) (%) -119.79
INFI's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. INFI: -119.79 )
INFI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3156.78   Max: 338.58
Current: -119.79

-3156.78
338.58
Revenue Growth (3Y)(%) -0.90
INFI's Revenue Growth (3Y)(%) is ranked higher than
76% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. INFI: -0.90 )
INFI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 155.9
Current: -0.9

0
155.9
EBITDA Growth (3Y)(%) -55.50
INFI's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -7.20 vs. INFI: -55.50 )
INFI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -64.6   Max: 261.4
Current: -55.5

-64.6
261.4
EPS Growth (3Y)(%) -37.90
INFI's EPS Growth (3Y)(%) is ranked higher than
59% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. INFI: -37.90 )
INFI' s 10-Year EPS Growth (3Y)(%) Range
Min: -64   Max: 115.9
Current: -37.9

-64
115.9
» INFI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

INFI Guru Trades in Q1 2014

John Burbank 16,556 sh (New)
Steven Cohen 3,411,659 sh (-4.05%)
Jim Simons 498,540 sh (-34.71%)
» More
Q2 2014

INFI Guru Trades in Q2 2014

Chuck Royce 123,400 sh (New)
Steven Cohen 3,410,978 sh (unchged)
John Burbank Sold Out
Jim Simons 198,600 sh (-60.16%)
Steven Cohen 3,411,659 sh (-4.05%)
» More
Q3 2014

INFI Guru Trades in Q3 2014

Paul Tudor Jones 16,163 sh (New)
Chuck Royce 135,400 sh (+9.72%)
Steven Cohen 500,000 sh (unchged)
Steven Cohen 1,700,000 sh (-50.16%)
Jim Simons 42,800 sh (-78.45%)
» More
Q4 2014

INFI Guru Trades in Q4 2014

Steven Cohen 52,476 sh (New)
Jim Simons 201,600 sh (+371.03%)
Steven Cohen Sold Out
Chuck Royce Sold Out
Paul Tudor Jones 12,679 sh (-21.56%)
» More
» Details

Insider Trades

Latest Guru Trades with INFI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.20
INFI's P/B is ranked higher than
78% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. INFI: 3.20 )
INFI' s 10-Year P/B Range
Min: 0.68   Max: 51.23
Current: 3.2

0.68
51.23
P/S 4.25
INFI's P/S is ranked higher than
87% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 30.13 vs. INFI: 4.25 )
INFI' s 10-Year P/S Range
Min: 1.32   Max: 60.95
Current: 4.25

1.32
60.95
PFCF 6.60
INFI's PFCF is ranked higher than
99% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INFI: 6.60 )
INFI' s 10-Year PFCF Range
Min: 2.17   Max: 48.64
Current: 6.6

2.17
48.64
POCF 6.66
INFI's POCF is ranked higher than
99% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INFI: 6.66 )
INFI' s 10-Year POCF Range
Min: 2.09   Max: 30
Current: 6.66

2.09
30
EV-to-EBIT -53.03
INFI's EV-to-EBIT is ranked higher than
59% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INFI: -53.03 )
INFI' s 10-Year EV-to-EBIT Range
Min: -193.5   Max: 493.6
Current: -53.03

-193.5
493.6
Current Ratio 6.28
INFI's Current Ratio is ranked higher than
80% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. INFI: 6.28 )
INFI' s 10-Year Current Ratio Range
Min: 0.67   Max: 17.67
Current: 6.28

0.67
17.67
Quick Ratio 6.28
INFI's Quick Ratio is ranked higher than
81% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. INFI: 6.28 )
INFI' s 10-Year Quick Ratio Range
Min: 0.53   Max: 17.67
Current: 6.28

0.53
17.67
Days Sales Outstanding 1.43
INFI's Days Sales Outstanding is ranked higher than
99% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 112.01 vs. INFI: 1.43 )
INFI' s 10-Year Days Sales Outstanding Range
Min: 0.18   Max: 831.54
Current: 1.43

0.18
831.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.10
INFI's Price/Net Cash is ranked higher than
90% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. INFI: 4.10 )
INFI' s 10-Year Price/Net Cash Range
Min: 1.1   Max: 38.43
Current: 4.1

1.1
38.43
Price/Net Current Asset Value 4.10
INFI's Price/Net Current Asset Value is ranked higher than
90% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. INFI: 4.10 )
INFI' s 10-Year Price/Net Current Asset Value Range
Min: 0.87   Max: 26.79
Current: 4.1

0.87
26.79
Price/Tangible Book 3.40
INFI's Price/Tangible Book is ranked higher than
85% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. INFI: 3.40 )
INFI' s 10-Year Price/Tangible Book Range
Min: 0.74   Max: 46
Current: 3.4

0.74
46
Price/Median PS Value 1.00
INFI's Price/Median PS Value is ranked higher than
86% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. INFI: 1.00 )
INFI' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 4.64
Current: 1

0.38
4.64
Earnings Yield (Greenblatt) -1.90
INFI's Earnings Yield (Greenblatt) is ranked higher than
80% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. INFI: -1.90 )
INFI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.9   Max: 4271.1
Current: -1.9

-1.9
4271.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:I3F.Germany,
Infinity Pharmaceuticals, Inc. was incorporated in California on March 22, 1995 under the name IRORI and, in 1998; the Company changed its name to Discovery Partners International, Inc. On September 12, 2006, Discovery Partners completed a merger with Infinity Pharmaceuticals, Inc., to which a wholly-owned subsidiary of Discovery Partners merged with and into the Company. The Company is a biopharmaceutical company engaged in discovering, developing and delivering medicines to people with difficult-to-treat diseases. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. The IPI-145, its primary product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K. The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in white blood cells, where they have distinct and mostly non-overlapping roles in immune cell development and function. For Hematologic Malignancies, the Company has launched DUETTS, an investigation of IPI-145 in blood cancers. As part of the DUETTS program, it is conducting DYNAMO, a Phase 2, open-label, single arm study evaluating the safety and efficacy of IPI-145 dosed at 25mg BID in approximately 120 patients with indolent non-Hodgkin lymphoma, or iNHL, including follicular lymphoma, marginal zone lymphoma and small lymphocytic lymphoma, whose disease is refractory to radio immunotherapy or both rituximab and chemotherapy. The FDA has granted orphan drug designation to IPI-145 for the potential treatment of follicular lymphoma. It is conducting DUO, a randomized, monotherapy Phase 3 study of IPI-145 in approximately 300 patients with relapsed/refractory chronic lymphocytic leukemia. For Inflammation and Autoimmune Diseases, the Company has completed a Phase 1, randomized, double-blind, placebo-controlled trial of IPI-145 in healthy adult subjects designed to support the development of IPI-145 in inflammatory and autoimmune diseases. The Company is also developing its second PI3K product candidate, a potent, oral inhibitor of PI3K-delta and gamma referred to as IPI-443. The nonclinical studies of IPI-443 required for Phase 1 development have been completed, and the data from the two Phase 2 studies of IPI-145 in inflammatory and autoimmune diseases will guide the next steps for the development of IPI-443. The Company has discovered IPI-940, a novel, orally available inhibitor of fatty acid amide hydrolase. It is believed that inhibition of FAAH may enable the body to bolster its own analgesic and anti-inflammatory response and may have applicability in a broad range of painful or inflammatory conditions. The Company has five issued or allowed U.S. patents covering IPI-145 and/or other molecules related to PI3K program, which expires on various dates between 2029 and 2031. In addition, it has approximately 170 patents and patent applications pending related to PI3K pro
» More Articles for INFI

Headlines

Articles On GuruFocus.com
own Mar 02 2015 
comment on INFI Mar 02 2013 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 04 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) May 06 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 06 2009 
Infinity Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Why Infinity Pharmaceuticals (INFI) Could Be Positioned for a Surge? - Tale of the Tape Mar 12 2015
Infinity Provides Company Update and Reports Full-Year 2014 Financial Results Mar 10 2015
4 Biotechs Expected to See Huge Buying on PowerShares Rebalance Mar 03 2015
JPM Securities Picks Through Biotech News For Winners Feb 25 2015
Infinity reports 4Q loss Feb 24 2015
Infinity reports 4Q loss Feb 24 2015
Infinity Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Feb 24 2015
INFINITY PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Feb 24 2015
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 24 2015
Infinity Provides Company Update and Reports Full-Year 2014 Financial Results Feb 24 2015
Q4 2014 Infinity Pharmaceuticals Inc Earnings Release - After Market Close Feb 24 2015
Infinity to Present at the RBC Capital Markets 2015 Healthcare Conference Feb 18 2015
Infinity to Present at the RBC Capital Markets 2015 Healthcare Conference Feb 18 2015
Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks - Earnings ESP Feb 17 2015
Interim Management Statement Feb 16 2015
Infinis Energy plc Interim Management Statement Feb 16 2015
Infinity Announces the Date of Its Full-Year 2014 Financial Results Conference Call and Webcast Feb 10 2015
Will Thoratec (THOR) Miss Earnings Estimates in Q4? - Analyst Blog Feb 06 2015
Infinity Provides Key 2015 Goals and Financial Guidance Jan 14 2015
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK